IDH1 inhibitor amplified the efficiency of glioma-associated antigens vaccination, augmented the infiltration of CD8 + T cell and improved the survival of mice challenged with IDH1mt tumor (Kohanbash et al., 2017). Here, CD8A is linked to central nervous system cancer.